BC Extra | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

Lung Therapeutics closes $36M series C  Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53...
BC Innovations | Feb 2, 2018
Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
BC Week In Review | Jul 28, 2017
Company News

4SC grants Maruho rights to KCNA3-targeted compounds

4SC AG (Xetra:VSC) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to a class of preclinical compounds targeting potassium channel Kv1.3 (KCNA3) . 4SC will be eligible for up to €103 million ($119.9 million) in...
BC Week In Review | May 19, 2017
Financial News

TetraGenetics receives JDRF T1D Fund investment

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Arlington, Mass.) on May 2. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. TetraGenetics Inc. , Arlington, Mass. ...
BC Extra | May 2, 2017
Financial News

Tetragenetics gets JDRF investment

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Cambridge, Mass.), the company said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. Tetragenetics said that by targeting ion...
BC Innovations | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv1.3 (KCNA3)

Cancer INDICATION: Cancer Patient sample, mouse and cell culture studies suggest promoting T cell expression of KCNA3 could help treat cancer. In patient tissue samples, interstitial fluid levels of potassium were higher in tumors than...
BC Week In Review | May 18, 2015
Clinical News

Dalazatide: Phase Ib data

Top-line data from the double-blind, Canadian Phase Ib 186-03 trial in 24 patients with active plaque psoriasis showed that twice-weekly 30 and 60 ug doses of subcutaneous dalazatide for 4 weeks were well tolerated. At...
BioCentury | May 11, 2015
Product Development

Check your effectors

Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence that targeting Kv1.3 channels may quell an active autoimmune response by halting activation of effector memory T cells while...
BC Innovations | Apr 16, 2015
Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
BC Week In Review | Apr 6, 2015
Clinical News

Airmid, Kineta preclinical data

In a rat model of anterior uveitis, topical ShK-186 reduced disease severity and inflammatory cell infiltration. Data were presented at the Ocular Diseases Drug Discovery meeting in San Diego. Kineta has exclusive, worldwide rights to...
Items per page:
1 - 10 of 34